PLEKHG6

Across TCGA pan-cancer cohorts, PLEKHG6 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLEKHG6 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PLEKHG6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PLEKHG6 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

STAD, UCEC, and ACC are the cancer types where PLEKHG6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	IV	0.001	0.544	<.001	24	view →
UCEC	DFS	Median	All	1.000	0.827	.009	20	view →
ACC	DFS	Median	All	0.079	0.674	<.001	16	view →
BLCA	OS	Median	II,III,IV	1.000	0.410	.027	10	view →
SARC	DFS	Median	All	0.121	0.591	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLEKHG6–STAD (OS)

Open the STAD breakdown →